A prospective, randomized, open-label study to compare the efficacy and safety of metformin versus metformin and fluoxetine in patients of type 2 diabetes mellitus with mild depression
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20252567Keywords:
Glycemic, HDRS, CGI, Quality of lifeAbstract
Background: Type 2 diabetes mellitus (T2DM) and depression often occur together, increasing morbidity and mortality. While metformin shows potential antidepressant effects, its comparative efficacy and safety versus metformin-fluoxetine (MF) combination in T2DM patients with mild depression required further study.
Methods: This prospective, randomized, open-label study involved 60 patients (18-65 years) with T2DM and mild depression (HDRS 8-13) over 90 days. Group A received metformin 500 mg twice daily (n=30), while group B received metformin 500 mg twice daily plus fluoxetine 40 mg daily (n=30). Primary outcomes included glycemic parameters (FPG, HbA1c) and depression scores (HDRS, CGI). Safety, quality of life, and compliance were also assessed.
Results: Baseline parameters were comparable between groups. Both groups showed highly significant improvements (p<0.001) in glycemic control and depression scores. Over 60 days, group A showed 20% HDRS improvement versus group B’s 10%; CGI-I was 3.33% in A versus 0% in B. By 90 days, HDRS improvement was 100% in group A versus 93.33% in B, while CGI-S and CGI-I improvements were 100% for both groups. No significant intergroup differences were observed for efficacy (p>0.05). Expected adverse effects were lower with metformin (28.33%) versus fluoxetine therapy (66.67%), all mild. Both groups demonstrated highly significant (p<0.001) QOL improvement and good compliance (≥85%).
Conclusions: Both treatments effectively improved glycemic control and depression symptoms. Metformin monotherapy demonstrated comparable efficacy and safety to the combination therapy of metformin and fluoxetine for managing mild depression in T2DM patients.
Metrics
References
Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. 2014;7(1):45-8. DOI: https://doi.org/10.4066/AMJ.2014.1979
Sartorius N. Depression and diabetes. Dialogues Clin Neurosci. 201;20(1):47-52. DOI: https://doi.org/10.31887/DCNS.2018.20.1/nsartorius
Guo M, Mi J, Jiang QM, Xu JM, Tang YY, Tian G, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 2014;41(9):650-6. DOI: https://doi.org/10.1111/1440-1681.12265
Poggini S, Golia MT, Alboni S, Milior G, Sciarria LP, Viglione A, et al. Combined fluoxetine and metformin treatment potentiates antidepressant efficacy increasing IGF2 expression in the dorsal hippocampus. Neural Plast. 2019;4651031. DOI: https://doi.org/10.1155/2019/4651031
Kant R, Yadav P, Barnwal S, Dhiman V, Abraham B, Gawande K. Prevalence and predictors of depression in type 2 diabetes mellitus. J Educ Health Promot. 2021;10:352. DOI: https://doi.org/10.4103/jehp.jehp_1507_20
Salinero-Fort MA, Gómez-Campelo P, San Andrés-Rebollo FJ, Cárdenas-Valladolid J, Abánades-Herranz JC, de Santa Pau EC, et al. Prevalence of depression in patients with type 2 diabetes mellitus in Spain (the DIADEMA Study): results from the MADIABETES cohort. BMJ Open. 2018;8(9):e020768. DOI: https://doi.org/10.1136/bmjopen-2017-020768
Somasundaram N, Kalra S, Shrestha D, Raza SA, Bhattacharya S, Sahay R, et al. Metformin for the treatment of type 2 diabetes in Asian adults: a systematic review. Diabetes Metab Syndr Obes. 2025;18:873-904. DOI: https://doi.org/10.2147/DMSO.S479889
González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Ramos-Zavala MG, Barrera-Durán C, González-Canudas J. Effect of metformin glycinate on glycated hemoglobin A1c concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2012;14(12):1140-4. DOI: https://doi.org/10.1089/dia.2012.0097
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491-7. DOI: https://doi.org/10.1016/S0002-9343(97)00254-4
Khazaie H, Rahimi M, Tatari F, Rezaei M, Najafi F, Tahmasian M. Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? Neurosci Riyadh Saudi Arab. 2011;16(1):42-5.
Yang Y, Zhang X, Zhang Y, Zhao J, Jia J, Liu H, et al. Metformin treatment improves depressive symptoms associated with type 2 diabetes: a 24-week longitudinal study. J Affect Disord. 2024;365:80-6. DOI: https://doi.org/10.1016/j.jad.2024.08.071
Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23(5):618-23. DOI: https://doi.org/10.2337/diacare.23.5.618
Bikas A, Van Nostrand D, Jensen K, Desale S, Mete M, Patel A, et al. Metformin attenuates 131I-induced decrease in peripheral blood cells in patients with differentiated thyroid cancer. Thyroid. 2016;26(2):280-6. DOI: https://doi.org/10.1089/thy.2015.0413
Gillani SW, Ghayedi N, Roosta P, Seddigh P, Nasiri O. Effect of metformin on lipid profiles of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Pharm Bioallied Sci. 2021;13(1):76-82. DOI: https://doi.org/10.4103/jpbs.JPBS_370_20
Patel CR, Patel DA, Patel DJ. Study of effect of metformin on lipid profile in type 2 diabetes mellitus in a tertiary care teaching hospital. Int J Pharm Sci Res. 2019;10:5553-8.
Ye Z, Chen L, Yang Z, Li Q, Huang Y, He M, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PloS One. 2011;6(7):21551. DOI: https://doi.org/10.1371/journal.pone.0021551
Manjarrez-Gutiérrez G, Herrera-Márquez R, Lara-Pérez G, Serrano-Hernández Y, Mondragón-Herrera JA, Hernández-Rodríguez J. Fluoxetine and metformin combined treatment decreases insulin resistance in patients with metabolic syndrome. Trends Diabetes Metab. 2020;3. DOI: https://doi.org/10.15761/TDM.1000117
Jalali M, Rahimlou M, Mahmoodi M, Moosavian SP, Symonds ME, Jalali R, et al. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials. Pharmacol Res.2020;159:104799. DOI: https://doi.org/10.1016/j.phrs.2020.104799
Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9(8):800-9. DOI: https://doi.org/10.1111/1753-0407.12555
Zhang Z, Dong H, Chen J, Yin M, Liu F. Effects of metformin on renal function, cardiac function, and inflammatory response in diabetic nephropathy and its protective mechanism. Dis Mark. 2022;2022(1):8326767. DOI: https://doi.org/10.1155/2022/8326767
Aksu U, Guner I, Yaman OM, Erman H, Uzun D, Sengezer-Inceli M, et al. Fluoxetine ameliorates imbalance of redox homeostasis and inflammation in an acute kidney injury model. J Physiol Biochem. 2014;70(4):925-34. DOI: https://doi.org/10.1007/s13105-014-0361-0
Nabrdalik K, Skonieczna-Żydecka K, Irlik K, Hendel M, Kwiendacz H, Łoniewski I, et al. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review, meta-analysis and meta-regression of randomized controlled trials. Front Endocrinol. 2022;13:975912. DOI: https://doi.org/10.3389/fendo.2022.975912
Mishra R, Krishan S, Siddiqui AN, Kapur P, Khayyam KU, Rai PK, et al. Impact of metformin therapy on health-related quality of life outcomes in tuberculosis patients with diabetes mellitus in India: a prospective study. Int J Clin Pract. 2021;75(4):e13864. DOI: https://doi.org/10.1111/ijcp.13864
Downloads
Published
How to Cite
Issue
Section
